Articles On NeuroScientific Biopharmaceuticals (ASX:NSB)

ShareCafeWebinar Recap – ECT, ATV, TZL, AO1 Catch up on the full webinar with presentations from Environmental Clean Technologies (ASX: ECT),  ActivePort (ASX: ATV), TZ Limited (ASX: TZL) & NeuroScientific Biopharmaceuticals (ASX: NSB)...

ShareCafeNeuroScientific Biopharmaceuticals (ASX: NSB) – Webinar Presentation Alexandra Andrews – Director Of Operations – Neuroscientific Biopharmaceuticals is developing novel peptide-based pharmaceutical products that target a number o...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

The broad Australian indices have started the day off in the red as the market resets from a number of stirrups this week. The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/AS...

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafePeptide based therapies for neurodegenerative conditions Dougal Thring  – VP Clinical Development – NeuroScientific Biopharmaceuticals is developing novel peptide-based pharmaceutical products that target a number of neurologi...

Neurological disorder specialist, Neuroscientific Biopharma (ASX:NSB), announced that research work on its lead drug EmtinB has received a tax incentive rebate under the R&D Tax Incentive program. The company said that it has been grant...

The breakthrough announcement by NeuroScientific Biopharma today elevates its lead drug EmtinB to hunt down the $20bn multiple sclerosis market. Australian drug development company NeuroScientific Biopharmaceuticals (ASX:NSB) announced that...

S&P 500 and Nasdaq at record highs again The US stock markets are coming home for a strong finish in August, with both the S&P 500 and Nasdaq lifting to record highs. The S&P 500 rose by 0.43%, the Nasdaq by 0.9%, but the Dow Jo...

Leading the health stocks today is Nanosonics (ASX:NAN)  up 19.69% after flagging FY21 revenues of $103.1 million, with strong momentum in H2 where revenues came in at $60 million – up 39% from H1. The company installed 3,030 units of its a...

Another red day for the ASX to close out the week. The ASX 200 closed 0.05% down from yesterday at 7,461 points, 2.2% lower than a week ago. The ASX Emerging Companies Index meanwhile dropped 2.09%, closing at 2,187 points which is over 5%...

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price jumped higher this morning before becoming subject to a trading halt at lunchtime. Before the pause in trading, the Australian biotech company’s shares were exchanging hand...

The broader ASX continued its losing streak, shedding another 0.5% while the benchmark ASX 200 closed at 7,465 points, which is 2.2% lower than last Friday’s close. Health and consumer discretionary goods were rays of sunshine with gains of...

Got 90 seconds? Then listen to Chairman, Paul Rennie tell us about their company news. Neuroscientific biopharmaceuticals (ASX:NSB) is an Australian biotechnology company developing novel disease modifying therapies for neurodegenerative di...

It wasn’t a happy start to the new financial year for Australia’s bourse, which lost nearly two thirds of one per cent today. Likewise, the ASX200, which rose 22% in FY21, closed down 0.65% to 7,266. Meanwhile, the ASX Emerging Companies In...

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) shares jumped more than 7% in early trade after the company released the readouts for the successful completion of its pivotal ocular safety study. Since then, however, the NeuroScientific...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

23 Jun 2021 - A snapshot of notable stock news for the hour, featuring ikeGPS Group, Wide Open Agriculture, Respiri & NeuroScientific Biopharmaceuticals.

23 Jun 2021 - NeuroScientific Biopharmaceuticals (ASX:NSB) has partnered with Linear Clinical Research to commence Phase 1 clinical trials for its lead drug candidate EmtinB.

Summary The ASX 200 traded lower by 27.30 points or 0.37% at 7,314.90 by afternoon, led by energy and banking stocks. Nine out of 11 sectoral indices were trading in the red, barring tech and materials. CBA expects the Reserve Bank of...

NeuroScientific Biopharmaceuticals (ASX:NSB) edged even closer to a planned Phase I clinical trial of EmtinBTM. The company has found a research partner in Perth-based Linear Clinical Research. Linear operates a clinical trials facility on...

Wall Street rebounds as Nasdaq resets record high All three major US benchmarks rose overnight, as investors adjusted to the Fed’s rate outlook. The Dow Jones rose by 0.20%, S&P 500 by 0.51%, and tech heavy Nasdaq by 0.79%. Nasdaq close...

After overseeing Paradigm Biopharmaceuticals’ (ASX:PAR) rise to 14-bagger highs, Paul Rennie has joined NeuroScientific Biopharmaceuticals (ASX:NSB) as Non-executive Chairman. The appointment is a substantial win for NeuroScientific given R...

Tech stocks lead global sell-off Tech and growth stocks mostly fell overnight, after US Treasury Secretary Janet Yellen said that interest rates may have to rise to cool down the economy. The comments have sparked a global equities sell-off...

Wall Street pulls back as tech stocks retreat All the major US indices fell last night. Dow Jones was down slightly by 0.3%, while S&P 500 and NASDAQ fell by 0.32% and 0.11% respectively. Tech stocks like Apple, Microsoft, Amazon, and F...

Summary Neuroscientific Biopharmaceuticals is collaborating with The Institute of Respiratory Health and The University of Western Australia to evaluate the efficacy of EmtinB and other compounds as a potential treatment for post-COVID f...

The company is partnering with The Institute of Respiratory Health and The University of Western Australia to test the effectiveness of EmtinB and other Metallothionein derived peptides as potential therapy for COVID-19 respiratory complica...

The company has received strong commitment for the placement, whose proceeds will be used to finish preclinical safety and toxicology programs in ophthalmology and neurology as well as accelerate the start of a Phase 1 study in patients suf...

Special Report: Early stage biotech NeuroScientific Biopharmaceuticals is developing peptide-based compounds that may prevent neurodegeneration and stimulate neuroregeneration. While its ... Read More The post NeuroScientific Biopharmaceuti...

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is up 20% today on the back of an ASX announcement about its lead compound EmtinB. In a preclinical study, the compound demonstrated positive preliminary results in a Multip...

NeuroScientific Biopharmaceuticals (ASX: NSB) has published positive preliminary results from a pre-clinical study of its lead compound EmtinB in treating multiple sclerosis (MS). The full report is set to be published by the end of this mo...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Backpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a greater risk in the suburb’s sandy stews. Antibiotic maker Recce Pharmaceuticals (ASX: RCE) says its lead candidate is proving to be effective ag...

Our summary of NeuroScientific Biopharmaceuticals Ltd's recent announcement What's happened? NeuroScientific Biopharmaceuticals Ltd (ASX: NSB, “NeuroScientific”) has announced it has received the Final Report from its recently completed gl...

The COVID-19 pandemic will result in changes to several industries and one of these is manufacturing. Since the early 1960s manufacturing as a percentage of Australian GDP has dropped from 30 per cent to 5.7 per cent now. Of course Australi...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, only nine were in positive territory over the last fortnight; nine were flat and 119 saw their share prices fall. Cod...

NeuroScientific Biopharmaceuticals (ASX: NSB) has achieved positive results in pre-clinical studies using its lead drug candidate EmtinB to treat multiple sclerosis models. Independent research organisation Neuron Experts undertook the stud...

NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed positive results from a glaucoma study on pig models that indicates the “disease-modifying potential” of its lead drug candidate EmtinB. The drug developer today announced outcomes...

Dementia already affects hundreds of thousands of people in Australia, and it’s only going to get worse if a medical miracle is not forthcoming. The term relates to brain diseases, including Alzheimers, that impact a person’s ability to thi...

ImpediMed’s (ASX:IPD) December quarter report includes the word ‘up’ eight times and the word ‘down’ not at all, and yet the company’s shares dropped nearly 17 per cent at market open. The stock fell from 17c to 14c. ImpediMed expects to on...

You may have heard the saying “it’s not brain surgery” in the context of trying to prove something easy. Well there is a reason  — our brains are among the most difficult parts of our body to treat. There are a few ASX small caps trying to...

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

Cancer is a crowded market, pot has sleep and pain issues covered — or so they say — and companies dip in and out of respiratory diseases all the time. But there are a few ASX-listed stocks that are tackling health issues that still rate as...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

Investors, brokers, high-ranking delegates, big pharma and Aussie small caps will all be sharing a room at the upcoming AusBiotech Invest & Partnering 2019 event in late October. The southern hemisphere’s biggest biotech investment even...

Special Report: The inaugural Biotech Luncheon in Perth launched with a bang, with more than 150 guests attending the event last week. Hosted by industry entrepreneur Brian Leedman, the luncheon was established to raise awareness of, and bu...

The WA investment community will turn its attention to healthcare next Thursday, when the annual Biotech Lunch takes place in Perth. Hosted by industry entrepreneur Brian Leedman, the luncheon will provide a forum for brokers and investors...